ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Forecasted to Post Q1 2026 Earnings of ($0.08) Per Share

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for ImmunoPrecise Antibodies in a research report issued to clients and investors on Tuesday, September 17th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS, FY2027 earnings at ($0.01) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.32 EPS.

ImmunoPrecise Antibodies (NASDAQ:IPA) last posted its quarterly earnings results on Monday, July 29th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.42). The company had revenue of $4.76 million during the quarter, compared to analysts’ expectations of $4.92 million. ImmunoPrecise Antibodies had a negative net margin of 110.66% and a negative return on equity of 57.05%.

Separately, Benchmark lowered their price target on ImmunoPrecise Antibodies from $5.00 to $3.00 and set a “speculative buy” rating for the company in a research report on Wednesday, August 14th.

ImmunoPrecise Antibodies Trading Up 14.0 %

Shares of ImmunoPrecise Antibodies stock opened at $0.66 on Wednesday. The firm has a market capitalization of $17.37 million, a price-to-earnings ratio of -1.61 and a beta of 0.10. ImmunoPrecise Antibodies has a fifty-two week low of $0.53 and a fifty-two week high of $2.60. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.15 and a current ratio of 1.41. The stock has a 50 day moving average of $0.79 and a 200 day moving average of $1.09.

Institutional Trading of ImmunoPrecise Antibodies

A hedge fund recently raised its stake in ImmunoPrecise Antibodies stock. Renaissance Technologies LLC raised its holdings in ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 70.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,910 shares of the company’s stock after buying an additional 26,310 shares during the period. Renaissance Technologies LLC owned about 0.24% of ImmunoPrecise Antibodies worth $65,000 as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.